Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Score 1
2011 pubmed

Haploinsufficiency in the prometastasis Kiss1 receptor Gpr54 delays breast tumor initiation, progression, and lung metastasis.

Cho. Sung-Gook SG; Wang. Ying Y; Rodriguez. Melissa M; Tan. Kunrong K; Zhang. Wenzheng W; Luo. Jian J; Li. Dali D; Liu. Mingyao M

Key Findings

  • Partial loss of KISS1R (heterozygosity) delays breast tumor initiation, growth, and lung metastasis in mice.
  • Kisspeptin‑10 binding to KISS1R activates RhoA via Gαq‑p63RhoGEF, promoting anchorage‑independent tumor growth.
  • Silencing KISS1R or inhibiting RhoA reduces Ras‑driven breast cell transformation in vitro.

Practical Outcomes

  • For most biohackers, the study offers no direct protocol or dosage advice. It suggests that stimulating KISS1R with kisspeptin‑10 could potentially support tumor growth, so caution is warranted if considering kisspeptin‑based interventions, especially for individuals at risk for breast cancer.

Summary

In mouse experiments, having only one working copy of the kisspeptin receptor (KISS1R) slowed down breast cancer start, growth, and spread to the lungs. Adding the peptide kisspeptin‑10 turned the receptor on, which then activated a RhoA signaling chain that helped cancer cells grow and form colonies. Knocking down the receptor or blocking RhoA reduced these cancer‑promoting effects.

Abstract

Activation of KISS1 receptor (KISS1R or GPR54) by its ligands (Kisspeptins) regulates a diverse function both in normal physiology and pathophysiology. In cancer, KISS1R has been implicated in tumor angiogenesis and metastasis, but a broader evaluation of KISS1R in tumorigenesis and tumor progression is yet to be conducted. In this study, we used mouse models of Kiss1r gene knockout and mouse mammary tumor virus-polyoma virus middle T antigen (MMTV-PyMT)-induced breast cancer to conduct such an evaluation. Kiss1r heterozygosity in MMTV-PyMT mice was sufficient to attenuate breast cancer initiation, growth, latency, multiplicity, and lung metastasis. To confirm these effects and assess possible contributions of endogenous ligands, we isolated primary tumor cells from PyMT/Kiss1r(+/+) and PyMT/Kiss1r(+/-) mice and compared their phenotypes by in vitro and in vivo assays. Kiss1r loss attenuated in vitro tumorigenic properties as well as tumor growth in vivo in immunocompromised NOD.SCID/NCr mice. Kiss1r activation in these cells, resulting from the addition of its ligand Kisspeptin-10, resulted in RhoA activation and RhoA-dependent gene expression through the Gαq-p63RhoGEF signaling pathway. Anchorage-independent growth was tightly linked to dose-dependent regulation of RhoA by Kiss1r. In support of these results, siRNA-mediated knockdown of KISS1R or inactivation of RhoA in human MCF10A breast epithelial cells overexpressing H-RasV12 was sufficient to reduce Ras-induced anchorage-independent growth. In summary, we concluded that Kiss1r attenuation was sufficient to delay breast tumor initiation, progression, and metastasis through inhibitory effects on the downstream Gαq-p63RhoGEF-RhoA signaling pathway.

Study Information

Provider

pubmed

Year

2011

Date

2011-08-18T00:00:00.000Z

DOI

10.1158/0008-5472.can-11-0329